The Clinical Features and Long-Term Follow-Up of Vitamin B6-Responsive Infantile Spasms in a Chinese Cohort

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Jun 1

PMID 35645976

Authors

Xianru Jiao

Pan Gong

Yue Niu

Zhao Xu

Ye Wu

Yuehua Zhang

Zhixian Yang

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the clinical features, treatment, and prognosis of patients with vitamin B6-responsive infantile spasms (IS).

Methods: The clinical features, genetics, and follow-up data of 30 patients were collected and analyzed.

Results: The age of epileptic spasms (ES) onset was from 3 months to 12 months. They all received high doses of vitamin B6 at different times after the onset of ES, ranging from 1 day to 5 months. ES were controlled within 11 days in 93% (28/30) patients, and as late as 1 month and 2 months in the other two patients. In the course of treatment, 28 patients were seizure-free all the time, and seizures of other two patients recurred due to withdrawal of vitamin B6. The available follow-up EEG results of 28 patients were normal in 26 cases, and 81% (21/26) had suppressed epileptic discharges within 6 months. Of the 26 cases with normal follow up EEG, 4 had developmental delay and 22 had normal development. The time for EEG to return to normal in 22 patients with normal development ranged from 14 days to 2 years (mean = 111.5 days; median = 52.5 days). The time for EEG to return to normal in the other 4 patients with development delay ranged from 4 months to 2 years (mean = 375 days; median = 330 days). To the last follow-up, seizures were controlled well in 29 surviving patients, and 21 patients were able to deactivate from all medications without seizures recurrence. Sixteen patients showed varying degrees of developmental delay after onset. After seizure control, the psychomotor development was delayed in 7 patients (one died) until the last follow-up. Genetic analysis did not show any meaningful results.

Conclusion: An observation period of 1-2 weeks is essential to identify patients with vitamin B6-responsive IS. The treatment time could be extended according to the treatment response and EEG changes. It might take a longer time for EEG to return to normal and to stop taking drugs in patients with persistent or unimproved developmental delay. Neurodevelopmental outcomes and prognosis of vitamin B6-responsive IS were relatively favorable.

References

Pietz J, Benninger C, Schafer H, Sontheimer D, MITTERMAIER G, Rating D . Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia. 1993; 34(4):757-63. DOI: 10.1111/j.1528-1157.1993.tb00458.x. View

Ohtahara S, Yamatogi Y, Ohtsuka Y . Vitamin B(6) treatment of intractable seizures. Brain Dev. 2011; 33(9):783-9. DOI: 10.1016/j.braindev.2011.01.010. View

Lux A, Osborne J . A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia. 2004; 45(11):1416-28. DOI: 10.1111/j.0013-9580.2004.02404.x. View

Ohtsuka Y, Ogino T, Asano T, Hattori J, Ohta H, Oka E . Long-term follow-up of vitamin B(6)-responsive West syndrome. Pediatr Neurol. 2000; 23(3):202-6. DOI: 10.1016/s0887-8994(00)00185-5. View

Nasiri J, Kachuei M, Kermani R, Samaninobandegani Z . Neurodevelopmental outcomes of the West syndrome in pediatric patients: The first report from the Middle-East. Res Dev Disabil. 2019; 89:114-119. DOI: 10.1016/j.ridd.2019.03.010. View

HUNT Jr A, STOKES Jr J, McCrory W, STROUD H . Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics. 1954; 13(2):140-5. View

Hamano S, Nagai T, Matsuura R, Hirata Y, Ikemoto S, Oba A . Treatment of infantile spasms by pediatric neurologists in Japan. Brain Dev. 2018; 40(8):685-692. DOI: 10.1016/j.braindev.2018.04.006. View

Blennow G, Starck L . High dose B6 treatment in infantile spasms. Neuropediatrics. 1986; 17(1):7-10. DOI: 10.1055/s-2008-1052491. View

Toribe Y . High-dose vitamin B(6) treatment in West syndrome. Brain Dev. 2001; 23(7):654-7. DOI: 10.1016/s0387-7604(01)00292-3. View

10.

Darin N, Reid E, Prunetti L, Samuelsson L, Husain R, Wilson M . Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B-Dependent Epilepsy. Am J Hum Genet. 2016; 99(6):1325-1337. PMC: 5142116. DOI: 10.1016/j.ajhg.2016.10.011. View

11.

Ohtsuka Y, Yamatogi Y, Yoshida H, Matsuda M, Iyoda K, Terasaki T . [High-dose pyridoxal phosphate in the treatment of the West and the Lennox syndromes]. No To Hattatsu. 1983; 15(3):225-33. View

12.

Xue J, Qian P, Li H, Wu Y, Xiong H, Zhang Y . Clinical characteristics of two cohorts of infantile spasms: response to pyridoxine or topiramate monotherapy. World J Pediatr. 2018; 14(3):290-297. DOI: 10.1007/s12519-018-0127-9. View

13.

Ohtsuka Y, Matsuda M, Ogino T, Kobayashi K, OHTAHARA S . Treatment of the West syndrome with high-dose pyridoxal phosphate. Brain Dev. 1987; 9(4):418-21. DOI: 10.1016/s0387-7604(87)80116-x. View

14.

Mills P, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M . Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med. 2006; 12(3):307-9. DOI: 10.1038/nm1366. View

15.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

16.

Mills P, Surtees R, Champion M, Beesley C, Dalton N, Scambler P . Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase. Hum Mol Genet. 2005; 14(8):1077-86. DOI: 10.1093/hmg/ddi120. View

17.

Imai Y, Yoshinaga H, Ishizaki Y, Watanabe Y, Ohtsuka Y . [Reappraisal of vitamin B6 therapy for West syndrome]. No To Hattatsu. 2009; 41(6):457-61. View

18.

Riikonen R, Mankinen K, Gaily E . Long-term outcome in pyridoxine-responsive infantile epilepsy. Eur J Paediatr Neurol. 2015; 19(6):647-51. DOI: 10.1016/j.ejpn.2015.08.001. View